Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.

Core Insights - CRISPR Therapeutics reported a significant decline in revenue, down 99.5% year over year, resulting in a per-share loss of $1.43, which is more than double the loss from the previous year [1] - Oppenheimer analyst Jay Olson has lowered the price target for CRISPR stock to $95 while maintaining an outperform rating [2] - The company is set to begin clinical trials for CTX112, a gene-editing treatment for systemic lupus erythematosus, and has a strong financial position with $2.1 billion in cash [3] Financial Performance - CRISPR experienced a quarterly negative free cash flow of $166.5 million, which is a significant reduction from the previous two quarters, providing the company with at least three years of runway before needing additional cash [4] - The FDA has approved CRISPR's Casgevy treatment for sickle cell anemia, marking it as the first CRISPR-based gene-editing therapy to reach the market [4] Revenue Potential - The revenue split from sales between CRISPR and Vertex Pharmaceuticals is projected to be 40-60, with early signs of encouraging momentum for the new treatment [5] - Analysts predict that CRISPR may not achieve profitability until 2028, with earnings expected to reach around $3.50 per share, but there are optimistic forecasts suggesting earnings could exceed $25 per share by 2030 [6]